Skip to main content

Gilead earnings slammed by legal settlement, stock falls

Gilead Sciences Inc. beat Wall Street's expectations for revenue in the fourth quarter, but the drugmaker's earnings were hit by $2 billion in unexpected costs, most of it due to a legal settlement.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.